ENTITY
Innovent Biologics Inc

Innovent Biologics Inc (1801 HK)

357
Analysis
Health CareChina
Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.
more
Refresh
22 Jul 2020 19:49

Innovent Biologics (信达生物) Placement - Back on the Market but This Time with Secondary Selldown

Innovent Biologics Inc (1801 HK) is looking to raise about U$290m to fund expansion and concurrently, shareholders are looking to sell about 33.8m...

Share
18 May 2020 15:32

Legend Biotech IPO Initiation: Choosing Therapies À La CAR-T

Legend Biotech (BLG US) is one of the leading companies in developing CAR-T cell therapies in China, having received clearance for the first CAR-T...

Logo
142 Views
Share
11 May 2020 14:25

Short Interest Spiked for China Gas, Country Garden Svc, Big Covers for Innovent

Hong Kong SFC reported today for aggregate short position on Apr 29. The aggregate short value for equities increased by $1,489m (+2.7%) WoW and...

Logo
234 Views
Share
23 Apr 2020 12:35

Akesobio: Trading Debut, Valuation Scenario Analysis

Akeso Biopharma Inc (9926 HK) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology...

Logo
461 Views
Share
14 Apr 2020 14:04

Akesobio IPO: Valuation Insights

Akeso Biopharma Inc (9926 HK) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology...

Logo
469 Views
Share
x